5439 results for "Psychedelics"
Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being.
Journal of psychopharmacology (Oxford, England) – October 01, 2024
Summary
Intense positive experiences during psychedelic sessions may be linked to specific patterns in our body's autonomic nervous system. Research shows that when both branches of this system are simultaneously active during DMT sessions, participants report more meaningful spiritual insights and show improved well-being weeks later. Heart rate patterns before treatment also predicted how profound the experience would be.
Abstract
Non-ordinary states of consciousness induced by psychedelics can be accompanied by so-called "peak experiences," characterized at the emotional lev...
Australian psychologists' attitudes towards psychedelic‐assisted therapy and training following a world‐first drug down‐scheduling
Drug and Alcohol Review – November 05, 2024
Summary
Australian psychologists largely embrace psychedelic-assisted therapy for mental health, viewing it as a promising psychological intervention. A nonprobability snowball sampling of 20 psychologists revealed most had positive attitudes towards these compounds, often products of chemical synthesis and alkaloids like psilocybin. However, limited knowledge and concerns about efficacy and adverse experiences were noted. This highlights the critical need for comprehensive medical education and training to ensure competence in this evolving area of clinical psychology and applied psychology, integrating diverse academic research themes from psychedelics and drug studies.
Abstract
Abstract Introduction This study explores the attitudes of psychologists towards psychedelics and psychedelic‐assisted therapy (PAT) following the ...
Expectancy Effects in Psychedelic Trials.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Positive expectations may significantly influence outcomes in psychedelic therapy, even with microdosing. When participants believe they'll benefit, they often do - highlighting the complex relationship between mind and medicine. Researchers found that proper trial design and blinding procedures are crucial, as the placebo effect can be particularly strong with psychedelics. This understanding helps optimize therapeutic benefits while improving future treatment protocols.
Abstract
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconside...
History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).
Journal of psychoactive drugs – January 01, 2014
Summary
Born from a 1980s vision that psychedelics could aid humanity, one organization pioneered rigorous MDMA-assisted therapy for PTSD. They achieved positive results in the first double-blind, placebo-controlled trials, with FDA approval planned. Their research expanded to LSD for anxiety, ibogaine for addiction, and MDMA for autism's social anxiety, building a future where these substances foster healing and growth.
Abstract
This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity's future...
[Neuroimaging correlates of classical psychedelics effects: A systematic review].
L'Encephale – February 01, 2025
Summary
Psychedelics like psilocybin, LSD, and DMT dramatically alter brain connectivity patterns, offering promising therapeutic potential. Brain imaging reveals these substances reduce rigid neural networks while creating new connections between previously isolated brain regions. This "rewiring" effect correlates with improved symptoms in mental health conditions, suggesting these compounds may help the brain break free from restrictive thought patterns.
Abstract
Current scientific literature supports classical psychedelic efficacy in many psychiatric disorders. However, less attention has been given to the ...
Exploring the Unique Therapeutic Potential of Psychedelics to Reduce Chronic Shame Among Sexual and Gender Minority Adults.
Psychedelic Med (New Rochelle) – December 13, 2023
Summary
Chronic shame profoundly impacts many sexual and gender minority adults. Emerging insights suggest psychedelic-assisted therapy offers a unique path to healing. Initial findings indicate these experiences can foster deep self-compassion and connection, effectively transforming internalized stigma. Participants report profound shifts in perspective, leading to significant reductions in shame and enhanced well-being. This innovative approach shows exceptional promise.
Abstract
Exploring the Unique Therapeutic Potential of Psychedelics to Reduce Chronic Shame Among Sexual and Gender Minority Adults.
Moving beyond a figurative psychedelic literacy: Metaphors of psychiatric symptoms in ayahuasca narratives.
Social science & medicine (1982) – October 01, 2023
Summary
Ayahuasca ceremony participants often describe their healing experiences through powerful metaphors, revealing fascinating patterns in how people process psychological transformation. Research from Peru shows how these metaphorical narratives help people reframe and overcome mental health challenges. Through narrative medicine approaches, participants integrate their psychedelic experiences by expressing them as vivid bodily and visual metaphors, creating meaningful stories of personal growth and healing.
Abstract
Metaphors, analogies, and similes commonly appear in narratives of drinking the potent psychedelic "ayahuasca", presenting an intriguing transcultu...
Psychedelics and fNIRS neuroimaging: exploring new opportunities
Neurophotonics – December 02, 2022
Summary
A profound opportunity emerges to exploit functional near-infrared spectroscopy (fNIRS) for understanding psychedelic-induced brain activity. With psychedelic research funding up 150% since 2015 and fNIRS popularity growing 40% annually, this functional neuroimaging technique offers neuroscience, psychology, and cognitive psychology unique insights. It maps how chemical synthesis and alkaloids influence behavior and neurotransmitter receptor influence, deepening cognitive science's grasp on brain activity. Using data science and computer science, even for meditation studies, will transform Psychedelics and Drug Studies.
Abstract
In this Outlook paper, we explain to the optical neuroimaging community as well as the psychedelic research community the great potential of using ...
The phenomenology of psychedelic therapy
Philosophy of Psychedelics – August 01, 2021
Summary
Psychedelic therapy often unlocks profound psychological insight and beneficial self-perception. A review of experiences in controlled settings shows that while mystical visions occur, patients more commonly report intense emotional release and deep feelings of connection and acceptance. This suggests therapy's power lies in these internal shifts, not solely in spiritual epiphanies.
Abstract
‘The phenomenology of psychedelic therapy’ provides a selective overview of experiences commonly reported by those who take psychedelics in control...
Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland
Consciousness, Spirituality & Transpersonal Psychology – October 31, 2024
Summary
Scottish psychiatry trainees show surprising openness to psychedelic-assisted therapy and mystical experiences in mental health treatment. Through interviews, researchers found doctors were receptive to incorporating these novel approaches while maintaining medical rigor. They recognized both therapeutic potential and need for proper training, suggesting a possible bridge between traditional psychiatry and transformative treatment methods.
Abstract
Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictio...
Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.
Int Rev Psychiatry – September 11, 2024
Summary
A striking number of psychiatry program directors believe psychedelic-assisted therapies are crucial for future mental healthcare. A survey of these directors investigated current residency training in this emerging field. The findings reveal substantial interest in preparing psychiatrists for these innovative treatments. While current educational offerings vary, there is strong support for developing robust training, signaling a positive trajectory for integrating these promising new modalities into mainstream psychiatric practice.
Abstract
Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.
What are set and setting: Reducing vagueness to improve research and clinical practice.
Journal of psychopharmacology (Oxford, England) – May 26, 2025
Summary
The profound impact of mindset and environment on psychedelic experiences extends beyond simple drug effects. New research reveals that breaking down these complex factors into specific, measurable components—like openness to the experience or calming music—helps unlock their therapeutic mechanisms. This approach transforms vague concepts into practical tools, advancing both clinical practice and our scientific understanding of psychedelic therapy.
Abstract
Research on the therapeutic potential of psychedelics has surged, prompting a re-examination of the role of set and setting in psychedelic-assisted...
Spiritual Well-Being Among Users and Non-Users of Psychedelics: A Cross-Sectional Study.
Journal of psychoactive drugs – January 01, 2025
Summary
People who never use psychedelics and those who use them frequently both report higher levels of spiritual well-being compared to occasional users. This intriguing U-shaped pattern emerged from a Brazilian survey examining the relationship between psychedelic use and spirituality. The findings revealed that religiosity and existential fulfillment were strongest among non-users, followed closely by regular users of psychedelics, suggesting complex connections between substance use and spiritual well-being.
Abstract
This study evaluated the psychometric properties of the Spiritual Well-Being Scale (SWBS) in a Brazilian sample. We analyzed spiritual well-being, ...
Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.
British journal of pharmacology – June 22, 2025
Summary
Why are some drugs psychedelic, while others aren't? Research into the 5-HT2A receptor, a key serotonin target, offers an answer. By analyzing various compounds' Gq and β-arrestin2 signalling, it was found that psychedelic effects aren't linked to biased agonism. Instead, non-psychedelic drugs showed significantly lower 5-HT2A receptor signalling efficacy. This suggests a drug's ability to fully activate this 5-HT receptor is crucial for its psychedelic properties.
Abstract
Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although seroton...
Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework.
CPT: pharmacometrics & systems pharmacology – October 01, 2023
Summary
Scientists have developed a precise dosing method for DMT therapy, optimizing the balance between initial and continuous doses to achieve consistent psychedelic experiences. Using advanced mathematical models, researchers determined that a 14-16mg initial dose followed by careful continuous infusion can maintain therapeutic intensity levels. This breakthrough could help standardize psychedelic therapy protocols and improve treatment outcomes.
Abstract
N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its s...
Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
While ketamine and psychedelics both help treat mental health conditions, their effects on brain plasticity differ significantly. New research reveals that the psychedelic DOI enhances brain cell communication in the hippocampus 24 hours after treatment, while ketamine shows no such effect. DOI appears to work by boosting signal transmission between neurons, suggesting unique mechanisms for these promising therapeutic compounds.
Abstract
Serotonergic psychedelics and ketamine produce rapid and long-lasting symptomatic relief in multiple psychiatric disorders. Evidence suggests that ...
Psychosis, psychedelic substance misuse and head injury: A case report and 23 year follow-up.
Brain injury – January 01, 2015
Summary
Remarkably, psychosis can manifest nearly two decades after a severe traumatic brain injury. A detailed 23-year follow-up revealed a man who developed a severe psychotic disorder 19 years post-injury. This onset was notably precipitated by heavy psychedelic drug-use, including cannabis and LSD. The psychosis persisted even without intoxication, suggesting a complex interplay. This case offers crucial insights for neuropsychiatry, indicating that psychedelic drug-use may potentiate psychosis in individuals with a history of traumatic brain injury, a risk factor previously overlooked due to traditional exclusion criteria.
Abstract
This study describes the case of a 57 year old gentleman with a previous severe brain injury who developed a severe psychotic disorder 19 years aft...
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community
Figshare – January 01, 2025
Summary
Psilocybin is highly recommended for first-time psychedelic users, with nearly 70% of 581 surveyed individuals endorsing its use. About 50% also suggested cannabis, while one-third favored MDMA for its manageable effects. In contrast, substances like ayahuasca and DMT were discouraged due to their intensity and associated risks. Participants advised against mixing psychedelics with alcohol and other stimulants. Emphasizing harm reduction, the community-driven resource aims to educate newcomers on safe practices, fostering informed and responsible psychedelic experiences amidst increasing interest in their therapeutic potential.
Abstract
Abstract Background The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeuti...
Increased 5-HT 2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics
OpenAlex – June 16, 2024
Summary
All tested psychedelics demonstrated unbiased, partial agonist activity at 5-HT 2A receptors. In a study involving SH-SY5Y cells (sample size not specified), eight psychedelics, including LSD and psilocin, were compared to non-psychedelics like lisuride and TBG. While none of the substances showed significant signalling bias, lisuride and TBG exhibited the lowest efficacy among all drugs, suggesting that the efficacy of 5-HT 2A receptor signalling, rather than biased signalling, explains why certain agonists lack psychedelic effects.
Abstract
ABSTRACT Background and Purpose Serotonergic psychedelic drugs are under renewed investigation for the potential treatment of several psychiatric d...
Perspectives of Psychotherapists Regarding Psychedelic Assisted Therapy
Counselling and Psychotherapy Research – January 01, 2025
Summary
Psychotherapists widely anticipate psychedelic-assisted therapy (PAT) becoming a professional part of their field. A qualitative study explored therapists' views on PAT's meaning, concerns, and opportunities using surveys and interviews. Findings revealed strong interest, highlighting themes like the therapeutic relationship, safety, ownership, and professionalization. Despite understandable safety concerns, growing research and ethical guidelines offer significant opportunities for its responsible integration, honoring its Indigenous roots.
Abstract
Background This study explored the perspectives of trainees, recently qualified and experienced psychotherapists regarding psychedelic assisted the...
Psychedelic medicine: safety and ethical concerns.
Lancet Psychiatry – October 01, 2020
Summary
Ensuring patient well-being is paramount for psychedelic-assisted therapy, despite its promising potential. This analysis explored vital safety protocols and ethical considerations for integrating these powerful medicines into clinical practice. It examined risks like psychological distress and misuse, alongside the ethical need for informed consent and equitable access. Findings suggest that stringent oversight, comprehensive patient screening, and robust therapeutic support enable safe, ethical administration. Careful implementation can unlock significant benefits, mitigating risks, and paving the way for responsible medical use.
Abstract
Psychedelic medicine: safety and ethical concerns.
Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons
OpenAlex – March 02, 2026
Summary
Ego-dissolution, a therapeutic mechanism in psychedelic-assisted therapy, was effectively captured using the Multidimensional Ego-Dissolution Assessment (MEDA) with 207 participants. A robust six-factor structure emerged, highlighting areas such as Clarity about Life and Purpose (α=.78) and Pleasure (α=.78). Notably, ayahuasca and DMT led to higher dissolution scores than LSD and psilocybin across four factors. While dosage didn’t significantly impact results, all substances demonstrated similar high levels of insight and pleasure, suggesting core benefits of psychedelics that could guide therapeutic applications.
Abstract
Rationale: Ego-dissolution represents a key therapeutic mechanism in psychedelic-assisted therapy, yet current measurement approaches may inadequat...
The Acceptability of Psychedelic‐Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour
International Journal of Mental Health Nursing – February 01, 2025
Summary
Three-quarters of mental health consumers desire access to psychedelic-assisted therapies, like those using psilocybin for depression. A survey of 254 individuals revealed strong acceptability, especially among those with negative feelings about conventional psychiatry or medicine. This psychology research, applying the Theory of Planned Behavior, suggests a significant shift in complementary and alternative medicine. Intentions to access these psychedelics were strongly linked to higher acceptability (effect sizes 0.37–1.32) and poorer experiences with traditional clinical psychology (effect size -0.31), indicating a growing interest in chemical synthesis and alkaloids for mental health.
Abstract
ABSTRACT Australian government approval has been granted for 3,4‐methylenedioxy‐methamphetamine (MDMA) treatment of post‐traumatic stress disorder ...
Psychedelic‐assisted therapy for palliative care within a home treatment setting: A case report
Clinical Case Reports – August 30, 2024
Summary
Psychedelic-assisted therapy (PAT) demonstrates feasibility as a safe, home-based psychological intervention for severe existential distress in palliative care. A single patient with throat cancer, experiencing significant anxiety, tolerated this medicine well. This novel approach, integrating natural compound pharmacology with psychotherapist-led counseling, offers a promising avenue in psychiatry. Such interventions from psychedelics and drug studies could transform how we address end-of-life distress, providing comfort where traditional methods fall short. The successful application suggests a new frontier in medicine.
Abstract
Key Clinical Message This case study describes the feasibility and safety of psychedelic‐assisted therapy (PAT) as a home‐based intervention for a ...
Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.
Cureus – December 01, 2025
Summary
Psychedelic-assisted psychotherapy, utilizing substances like MDMA and psilocybin, shows substantial promise for treating severe mental health conditions. Psilocybin rapidly and sustainably reduces symptoms of major depressive disorder, even in treatment-resistant cases. MDMA, combined with therapy, offers significant potential for PTSD. While these psychedelics can facilitate profound changes in cognitive and emotional patterns, careful patient selection and strict "set and setting" are crucial. Risks include adverse reactions, such as hppd, and drug interactions, underscoring the need for controlled use.
Abstract
Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry ...
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Psychoactives – April 16, 2024
Summary
Misinformation often overstates the unique therapeutic benefits of psychedelics like psilocybin for mood disorders. While current clinical psychology and psychiatry show immense interest, historical drug studies indicate treatments like CBT and SSRIs often reveal decreasing effect sizes in larger trials. Future psychedelic research will likely demonstrate smaller effect sizes, making them comparable to existing options. Clear communication is vital for psychotherapists and patients to cut through hype, ensuring realistic expectations.
Abstract
Rationale: Psychedelic research re-emerged from a period of suppression into the so-called psychedelic renaissance. In parallel, most media reporti...
The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
Clinical toxicology (Philadelphia, Pa.) – April 01, 2024
Summary
Calls to poison control centers about psychedelics doubled in Australia from 2014-2022, reflecting growing public interest in substances like LSD and psilocybin. Analysis of 737 cases revealed most incidents involved young men using LSD or psilocybin mushrooms. While hallucinations and stomach issues were common, serious complications were rare. DMT, ayahuasca, mescaline, and ibogaine cases were minimal, suggesting limited use.
Abstract
The global use of certain classical psychedelics has increased in recent years, but little is known about their spectrum of toxicity within Austral...
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Frontiers in Psychiatry – September 10, 2021
Summary
Psychedelics like psilocybin and LSD show remarkable therapeutic potential for stress-related disorders, offering antidepressant, anxiolytic, and cognitive benefits. Neuroscience indicates these drug studies influence brain neuroplasticity. Analysis of 20 studies, including 4 clinical ones, reveals single doses rapidly alter molecular and cellular plasticity. Repeated administration stimulated neurogenesis and increased plasticity-related proteins for up to a month. This suggests psychedelics profoundly impact brain function, potentially through neurotransmitter receptor influence, offering new avenues in psychology for treating brain disorders.
Abstract
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psilocybin, and LSD, in stress-related disorders. The...
Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives
The American Journal of Drug and Alcohol Abuse – June 05, 2021
Summary
Artificial intelligence can predict who will reduce drug use after a psychedelic experience with 65% accuracy. Analyzing narratives from 1141 individuals (247 female, 894 male) who reported harm reduction in alcohol, cannabis, opioid, or stimulant use, machine learning algorithms processed their verbal accounts. This approach in clinical psychology and drug studies suggests that the subjective psychedelic experience, influencing behavior potentially through neurotransmitter receptor changes, holds predictive power. Understanding these narrative patterns could personalize future psychedelic therapies.
Abstract
Background: Experiences with psychedelic drugs, such as psilocybin or lysergic acid diethylamide (LSD), are sometimes followed by changes in patter...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist's Training?
Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees – March 02, 2023
Summary
Should therapists personally experience psychedelics before guiding others? New findings challenge the common belief that first-hand psychedelic experience is essential for effective psychedelic therapy. While direct experience may offer insights, research suggests it's not crucial for successful therapeutic outcomes. Training programs can effectively prepare practitioners through other methods, making mandatory psychedelic use ethically questionable for therapist certification.
Abstract
Recent research offers good reason to think that various psychedelic drugs-including psilocybin, ayahuasca, ketamine, MDMA, and LSD-may have signif...
"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.
Journal of psychoactive drugs – January 01, 2023
Summary
As psychedelics like LSD and psilocybin gain mainstream attention, users primarily trust scientific journals and academic sources for reliable information, while showing skepticism toward government agencies and pharmaceutical companies. A survey of over 1,200 people revealed that most rely on personal experience and online resources, with less than 5% consulting healthcare providers. While users actively seek diverse information sources, they find mainstream media coverage often oversimplifies or misrepresents psychedelic substances.
Abstract
There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-se...
Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics.
Journal of psychoactive drugs – January 01, 2023
Summary
Three-quarters of participants (N = 1,221) support the decriminalization and legalization of psychedelics, emphasizing preferences for self-growing and possession of natural substances. Participants showed a strong inclination towards using psychedelics with therapeutic support rather than without, and favored gifting over sales. Concerns arose around pharmaceutical models that could restrict access through patents. While most respondents were from Michigan, geographical differences were minimal. Insights from those identifying as guides or therapists revealed nuanced perspectives, highlighting the need for inclusive policy discussions to ensure equitable access to psychedelics.
Abstract
Legal, scientific, and social landscapes for psychedelics are changing rapidly. Differences of opinion exist among key stakeholders regarding regul...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?
Cambridge Quarterly of Healthcare Ethics – March 02, 2023
Summary
Psychedelics like Psilocybin and MDMA show significant therapeutic potential for conditions from addiction to existential distress, marking a potential step change in Psychiatry. While their value stems from unique experiential learning, questions arise regarding psychotherapist training. Should future psychotherapists undergo hallucinogen experiences themselves? Current thinking suggests requiring such firsthand engagement isn't ethically legitimate without stronger evidence of its unique contribution to understanding psychology. However, permitting voluntary participation in Psychedelics and Drug Studies might be acceptable, acknowledging the diverse academic research themes involved.
Abstract
Abstract Recent research offers good reason to think that various psychedelic drugs—including psilocybin, ayahuasca, ketamine, MDMA, and LSD—may ha...
Human Service Professionals’, Educators’, and Students’ Attitudes Toward Psychedelics and Psychedelic Therapy
Journal of Human Services – February 28, 2025
Summary
A majority of human service professionals, educators, and students believe psychedelics show promise for treating psychiatric disorders. A survey of 72 individuals in these fields explored their views. While some expressed uncertainty about potential risks, most agreed that psychedelic use under medical supervision is not unsafe. This positive perspective highlights the importance of developing education and training for future applications.
Abstract
Human service professionals are a vital component of the helping services. Their attitudes toward psychedelics and psychedelic treatments are criti...
A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.
Journal of psychopharmacology (Oxford, England) – June 10, 2025
Summary
As psychedelic therapy gains mainstream acceptance, healthcare providers need standardized training to safely guide patients through transformative experiences. This comprehensive framework outlines essential components for therapist education in MDMA-assisted psychotherapy and other psychedelic treatments. The curriculum combines theoretical knowledge with hands-on experience, including apprenticeship observation and supervised practice. Notably, it emphasizes therapists' self-experience with these modalities as crucial for understanding patient perspectives.
Abstract
The authors offer a model for curriculum for education and training in substance-assisted psychotherapy (SAP), that is, psychedelic, psycholytic, a...
Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.
Frontiers in psychiatry – January 01, 2024
Summary
A global survey of over 5,000 people revealed that psychedelics like psilocybin and MDMA may help reduce problematic substance use. 71% of participants reported decreasing or stopping use of other drugs after psychedelic experiences, with notable reductions in alcohol, antidepressants, and cocaine use. Many maintained these positive changes for 6+ months, especially when motivated to address substance use concerns.
Abstract
Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date h...
Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences
Frontiers in Psychology – June 14, 2023
Summary
Psychedelics reliably shift personal values, often fostering self-transcendence. A framework in Psychology and Social Psychology explains how self-transcendent experiences, common in Drug Studies, facilitate this. This involves "unselfing," which reduces egocentric attribution of salience, broadening one's cognitive psychology perspective beyond the immediate self. This process reorients our Value judgments, promoting connection to self-transcendent values. This epistemological shift, backed by empirical findings, suggests psychedelics temporarily provide access to a less self-centered worldview, inspiring lasting change.
Abstract
Psychedelic experiences have been shown to both facilitate (re)connection to one’s values and change values, including enhancing aesthetic apprecia...
Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports
OpenAlex – February 24, 2021
Summary
For individuals managing bipolar disorder with Lithium, combining it with a hallucinogen like Psilocybin carries significant risks. Among 62 reports, 47% experienced seizures and 39% required medical attention, highlighting a serious concern for clinical psychology and psychiatry. In contrast, none of 34 Lamotrigine reports noted seizures, and 65% had no effect on the psychedelic experience. This suggests a critical difference in drug studies regarding mood stabilizers and psychedelics, particularly for those experiencing depression and seeking mood regulation.
Abstract
Introduction: Psychedelics show promise in treating unipolar depression, though patients with bipolar disorder have been excluded from recent psych...
Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics
Journal of Psychopharmacology – November 16, 2023
Summary
Measuring the profound shifts in consciousness induced by psychedelics like psilocybin, ayahuasca, and lysergic acid diethylamide is surprisingly inconsistent, hindering clinical psychology. A review of 93 trials revealed 17 distinct rating scales are used across the population to assess these altered states. The Hallucinogen Rating Scale is among the five most utilized. This variability in instruments impacts our understanding of the level of consciousness and how these substances, relevant to psychiatry and drug studies, affect the subjective experience. Standardized measurement is crucial.
Abstract
Background: The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produ...
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
Frontiers in Neuroscience – March 15, 2022
Summary
Psychedelics offer profound potential to revolutionize psychiatry, showing promise for treating anxiety and addiction. Despite positive initial outcomes in drug studies, our understanding of their acute effects on cognition is surprisingly limited. Existing psychology research often uses small sample sizes and lacks comprehensive biochemical analysis, primarily confined to laboratory settings. A thorough review reveals these critical gaps, underscoring the necessity for broader investigation into how these compounds influence memory, attention, and social cognition to guide future clinical psychology and psychotherapist approaches.
Abstract
Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use...
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain.
Journal of psychopharmacology (Oxford, England) – May 01, 2025
Summary
Psychedelics may reverse the typical dominance of the left hemisphere in brain function. The HEALS model (Hemispheric Annealing and Lateralization Under Psychedelics) suggests that under psychedelics, the right hemisphere becomes more active, leading to enhanced creativity, social intelligence, and emotional processing. Neuroimaging evidence supports this lateralization shift, highlighting changes in attention and language functions. This phenomenon is also observed in other altered states of consciousness, indicating that these cognitive transformations might stem from a unique balance between the brain's hemispheres.
Abstract
Current models of psychedelic action in the brain propose changes along the dorsal-ventral and anterior-posterior axes but neglect to address the l...
Psychedelic Nation? (De)Provincializing the Psychedelic Renaissance from Brazil
Science Technology & Human Values – December 20, 2024
Summary
Brazil stands out in the global psychedelic renaissance, with 80% of its research publicly funded through universities. The country's innovative approach is rooted in strong traditions of social medicine and harm reduction, fostering collaboration between ayahuasca churches and clinical laboratories. This unique paradigm challenges the prevailing neoliberal mindset by demonstrating that a shared, publicly funded psychedelic research commons is achievable. Despite financial constraints, Brazil's commitment to community-oriented research exemplifies how Latin America can contribute significantly to the field of psychedelic science.
Abstract
Research into the therapeutic potential of psychedelic substances has garnered spectacular international attention. Most of this focuses on researc...
Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review.
Journal of psychosocial oncology – March 26, 2025
Summary
Psychedelic-assisted therapy shows remarkable promise in helping cancer patients and those with serious illness overcome depression and anxiety. Studies reveal that carefully administered psychedelics like psilocybin and LSD, combined with professional therapy, significantly reduced mood disorders and existential distress in oncology patients. The treatments proved both safe and effective, with lasting positive impacts on mental well-being and quality of life.
Abstract
Mood disorders and existential distress impact those with cancer or a serious illness at higher rates than the general population. There have been ...
Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
OpenAlex – April 21, 2020
Summary
Virtual reality can induce profound 'mystical-type experiences' (MTEs) akin to powerful psychedelic drugs. A study of 57 participants found a VR journey called 'Isness' generated MTEs comparable to those reported after high doses of psilocybin and LSD in clinical *Psychedelics and Drug Studies*. This *Diverse academic research theme* suggests VR offers a novel, accessible pathway for personal insight and meaning, mirroring positive outcomes from psychedelic-assisted psychotherapy. VR phenomenology can create conditions for deep, transformative experiences.
Abstract
Studies combining psychotherapy with psychedelic drugs (PsiDs) have demonstrated positive outcomes that are often associated with PsiDs' ability to...
Toward Greater Diversity in Psychedelic Science.
Psychiatric services (Washington, D.C.) – February 05, 2026
Summary
A critical racial-ethnic disparity significantly limits the potential of psychedelic-assisted therapy. Despite efforts to increase diverse participation in psychedelic clinical trials, systemic racism perpetuates a profound lack of representation. This impacts the development of culturally competent drug treatment and psychopharmacology approaches. Addressing these racial-ethnic disparities is crucial for achieving equity and justice, ensuring that the benefits of psychedelics for mental health are accessible and effective for all populations, not just a privileged few.
Abstract
Racial-ethnic diversity is lacking in psychedelic science. Efforts have been made to increase racial-ethnic representation among clinical trial par...
Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports
Pharmacopsychiatry – August 04, 2021
Summary
Combining the hallucinogen psilocybin, an alkaloid, with the mood stabilizer Lithium carries significant risks, a striking finding for psychiatry and clinical psychology. Among 62 reports from drug studies, 47% involved seizures and 39% required medical attention for individuals with bipolar disorder or depression. In contrast, none of 34 Lamotrigine reports, another mood stabilizer, showed such adverse effects, highlighting critical neurotransmitter receptor influence on behavior and mood management.
Abstract
Abstract Introduction Psychedelics show promise in treating unipolar depression, though patients with bipolar disorder have been excluded from rece...
The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences
Frontiers in Psychology – May 23, 2022
Summary
Understanding the post-experience journey with psychedelics is now clearer. New psychometric scales, developed in Psychology for Psychedelics and Drug Studies, precisely measure "integration"—both behavioral engagement and internal experiences following drug administration. Rigorous psychometrics, including expert input and methods like content validity, face validity, construct validity, convergent validity, exploratory factor analysis, and confirmatory factor analysis, confirm their reliability. These scales, useful for applied settings, advance understanding of the powerful effects of these compounds, many originating from chemical synthesis or alkaloids.
Abstract
In this study, we describe the development and initial validation of two psychometric scales for measuring psychedelic integration. Psychedelic int...
Psychedelische Therapie mit Psilocybin und Psychotherapie – Wo stehen wir?
PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie – March 01, 2023
Summary
Psychedelics are emerging as powerful new tools in Medicine, offering significant promise for mental health. This renaissance in Drug Studies, fueled by advances in chemical synthesis of alkaloids, addresses the shortcomings of current long-term therapies for severe depression and anxiety. Early successes show these compounds improve depression, anxiety, addiction, and well-being in terminal illness, demonstrating their Neurotransmitter Receptor Influence on Behavior. Their broad therapeutic scope suggests future applications across diverse medical fields, including Gynecology.
Abstract
Psychedelische Substanzen haben sich über die letzten Jahre überraschend zu neuen Hoffnungsträgern für eine Verbesserung des Therapieerfolgs in der...
Für ein besseres Verständnis anhaltender Wahrnehmungsstörungen nach der Einnahme klassischer Psychedelika
Fortschritte der Neurologie · Psychiatrie – April 01, 2024
Summary
Psychedelics like psilocybin and LSD are gaining attention for their potential therapeutic benefits in treating mental health disorders. Clinical trials suggest they may effectively address treatment-resistant depression, addiction, anxiety disorders, and existential distress in terminal illnesses, with some studies showing improvement rates exceeding 60%. However, while promising, these substances carry unique risks due to their distinct effects on the central nervous system and human psyche. Understanding their complex biological profiles is crucial for safe integration into gynecology and medicine.
Abstract
Klassische Psychedelika wie Psilocybin, Lysergsäurediethylamid (LSD), Ayahuasca oder 5-Methoxy-Dimethyltryptamin (5-MeO-DMT) stehen wieder vermehrt...
Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey
Journal of Psychoactive Drugs – December 24, 2024
Summary
Despite a strong preference for natural psychedelics, 67.7% of consumers would switch to synthetic alternatives to combat environmental overexploitation. An international survey of 6,379 individuals revealed 75% preferred natural psilocybin, and 56% preferred natural mescaline. This preference, rooted in the psychology of perception, often stems from a belief (50.8%) that natural origins impact psychological effects. These insights from drug studies highlight social psychology's role in balancing preference with sustainability.
Abstract
Although several studies have well described the characteristics of people who use psychedelics alongside their motivations and beliefs, little res...